32,298 Shares in Johnson & Johnson $JNJ Acquired by Capital International Inc. CA

Capital International Inc. CA acquired a new stake in Johnson & Johnson (NYSE:JNJ) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 32,298 shares of the company’s stock, valued at approximately $5,989,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Abich Financial Wealth Management LLC purchased a new stake in shares of Johnson & Johnson during the third quarter valued at $26,000. Evolution Wealth Management Inc. bought a new stake in Johnson & Johnson during the 2nd quarter valued at about $27,000. Clayton Financial Group LLC purchased a new stake in Johnson & Johnson in the 3rd quarter valued at about $28,000. Semmax Financial Advisors Inc. grew its stake in Johnson & Johnson by 55.0% in the 2nd quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock worth $31,000 after acquiring an additional 72 shares in the last quarter. Finally, Compass Financial Services Inc grew its stake in Johnson & Johnson by 707.1% in the 3rd quarter. Compass Financial Services Inc now owns 226 shares of the company’s stock worth $42,000 after acquiring an additional 198 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Insider Activity

In related news, EVP Vanessa Broadhurst sold 6,197 shares of the business’s stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $243.39, for a total transaction of $1,508,287.83. Following the completion of the transaction, the executive vice president owned 23,003 shares in the company, valued at $5,598,700.17. The trade was a 21.22% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Timothy Schmid sold 1,322 shares of the stock in a transaction that occurred on Friday, February 20th. The shares were sold at an average price of $245.66, for a total transaction of $324,762.52. Following the sale, the executive vice president directly owned 25,447 shares of the company’s stock, valued at $6,251,310.02. The trade was a 4.94% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 30,142 shares of company stock valued at $7,360,528. Insiders own 0.16% of the company’s stock.

Key Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: FDA approval of TECVAYLI (teclistamab) plus DARZALEX FASPRO for relapsed/refractory multiple myeloma broadens J&J’s oncology offering and could accelerate uptake in earlier lines of therapy, supporting revenue growth expectations. Johnson & Johnson (JNJ) Announces the FDA Approval of TECVAYLI® plus DARZALEX FASPRO®
• Positive Sentiment: EU approval to expand Akeega’s use in BRCA‑mutated metastatic hormone‑sensitive prostate cancer increases the drug’s addressable market in Europe and should support oncology franchise sales. JNJ Gets EU Nod for Expanded Use of Akeega in Prostate Cancer
• Positive Sentiment: JNJ filed with the EMA to expand TECVAYLI monotherapy into earlier-line relapsed/refractory multiple myeloma after MajesTEC‑9 phase III data showing survival gains — a regulatory pathway that could materially extend TECVAYLI’s market. JNJ Seeks Label Expansion of Multiple Myeloma Drug Tecvayli in the EU
• Positive Sentiment: Citigroup raised its price target to $274 and kept a Buy rating, implying notable upside vs. current levels — analyst support that can help lift investor sentiment. Benzinga
• Neutral Sentiment: JNJ presented at Barclays’ Global Healthcare Conference (transcript available) — useful for management commentary on growth drivers but unlikely to move the stock by itself. Johnson & Johnson (JNJ) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
• Neutral Sentiment: Coverage pieces (valuation review, inclusion on a “safest dividend aristocrats” list) are drawing renewed investor attention but don’t directly change fundamentals. Assessing Johnson & Johnson (JNJ) Valuation
• Negative Sentiment: Short interest rose ~20.8% in late‑Feb to ~25.1M shares, increasing potential downside pressure if bearish sentiment persists or if volatility triggers additional selling. Article: Short interest report
• Negative Sentiment: Two J&J units agreed to pay $65M to settle a Tracleer antitrust class action — a modest hit to cash and an added legal overhang, though not material to enterprise value. Johnson & Johnson (JNJ) Units to Pay $65 Million in Tracleer Antitrust Class Action Settlement, Reuters Reports

Johnson & Johnson Stock Down 0.3%

Johnson & Johnson stock opened at $243.06 on Thursday. The company has a quick ratio of 0.77, a current ratio of 1.03 and a debt-to-equity ratio of 0.48. The firm has a market cap of $585.75 billion, a P/E ratio of 22.00, a P/E/G ratio of 2.41 and a beta of 0.34. The business has a fifty day moving average of $230.52 and a two-hundred day moving average of $205.54. Johnson & Johnson has a twelve month low of $141.50 and a twelve month high of $251.71.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Saturday, January 31st. The company reported $2.46 earnings per share (EPS) for the quarter. The business had revenue of $24.28 billion for the quarter. Johnson & Johnson had a return on equity of 33.04% and a net margin of 28.46%. On average, analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, March 10th. Shareholders of record on Tuesday, February 24th were issued a $1.30 dividend. The ex-dividend date was Tuesday, February 24th. This represents a $5.20 dividend on an annualized basis and a yield of 2.1%. Johnson & Johnson’s payout ratio is currently 47.06%.

Analyst Ratings Changes

JNJ has been the subject of several research analyst reports. Scotiabank reaffirmed an “outperform” rating on shares of Johnson & Johnson in a research note on Thursday, January 22nd. HSBC raised their price objective on Johnson & Johnson from $240.00 to $265.00 and gave the stock a “buy” rating in a report on Friday, January 30th. Argus upped their target price on Johnson & Johnson from $210.00 to $240.00 in a report on Friday, January 23rd. The Goldman Sachs Group restated a “buy” rating and set a $250.00 price target on shares of Johnson & Johnson in a research note on Thursday, January 22nd. Finally, Royal Bank Of Canada lifted their price objective on Johnson & Johnson from $240.00 to $255.00 and gave the company an “outperform” rating in a report on Tuesday, February 3rd. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $235.91.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.